Pramipexole di-HCl

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D219R0051

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
The Defense Logistics Agency (DLA) Troop Support, a federal office, has issued a solicitation for the supply of Pramipexole di-HCl, a pharmaceutical product classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) and Product Service Code 6505 (Drugs and Biologicals). This procurement is intended to secure a reliable supply of Pramipexole di-HCl, a medication commonly used in the treatment of Parkinson’s disease and related neurological disorders, for use by federal agencies and military personnel. The scope of this solicitation encompasses the manufacturing and delivery of Pramipexole di-HCl in accordance with the specifications and requirements outlined in the solicitation documents. The intended outcome is to ensure uninterrupted access to this critical pharmaceutical, supporting the health and operational readiness of the agency’s beneficiaries. The contract has undergone several modifications to address regulatory compliance and operational needs, including the incorporation of Drug Supply Chain Security Act language, and the addition of federal acquisition clauses such as FAR 52.204-27 (Prohibition on a ByteDance Covered Application), FAR 52.204-24, and FAR 52.205-25, which pertain to telecommunications and video surveillance equipment restrictions. The solicitation has also been amended to extend the closing date to December 31, 2019, at 3:00 PM EST, and to correct administrative details such as submission instructions and the Statement of Work. Multiple contract options have been invoked over the lifecycle of the contract, with effective dates spanning from April 29, 2021, through April 28, 2024, indicating a multi-year procurement strategy designed to maintain continuity of supply. Key requirements for prospective contractors include compliance with all relevant federal regulations, including those related to drug supply chain security and prohibitions on certain telecommunications applications. Offerors must be capable of manufacturing pharmaceutical preparations to the standards required by the DLA Troop Support and must adhere to the submission instructions and Statement of Work as corrected in the solicitation amendments. The contracting entity for this opportunity is DLA Troop Support, located within the federal government structure. The primary point of contact for this solicitation is Phyllis Daraio, who can be reached at [email protected] or by phone at 215-737-7941. Interested parties are encouraged to review the solicitation and its 14 attachments, available via the SAM.gov opportunity link: https://sam.gov/opp/56e63357e4844b96a16197487de02a11/view. This is a solicitation notice, and contractors should note that the opportunity remains active as of the post date (July 3, 2024). There is no indication of set-aside requirements or special considerations beyond the regulatory clauses and amendments specified. Contractors with capabilities in pharmaceutical preparation manufacturing and experience in federal contracting are encouraged to evaluate this opportunity for alignment with their expertise and operational capacity.
Documents14